RMI incorporated serum CA125 levels, ultrasound score, and menopausal status in the formula to predict the risk of ovarian malignancies, whereas ROMA, combined with serum CA125 and HE4 could predict the risk of ovarian malignant tumors before and after menopause, according to the menopausal status. Here, WFDC2 is linked to ovarian cancer.